Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, July 2, 2013 /CNW/ - At the 88th annual Canadian Dermatology Association Conference held in Quebec City
over the July 1st weekend, Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher") announced
the Canadian launch of Epuris™, a novel brand formulation of the acne medication isotretinoin for the
treatment of severe acne in patients aged 12 years or older.
The Canadian Dermatology Association estimates that acne affects nearly
20%, or 5.6 million, Canadians and that more than 80% of acne sufferers
are between the ages of 12 and 24. According to IMS Health, Canadian
isotretinoin sales reached $15 million in 2012.
"We are pleased to announce the launch of Epuris, a valuable new
treatment option for Canadian dermatologists and their patients who
suffer from severe acne," said Larry Andrews, CEO of Cipher. "This
represents an important milestone on the path to building Cipher's
commercial portfolio and franchise in Canada. We expect this will be
the first of a number of products we introduce, beginning in
Dermatology and, over time, in other specialty markets."
Epuris (isotretinoin) is a treatment for severe acne with the
well-established clinical benefits physicians know and the reliable
absorption and flexible dosing that both patients and physicians need.
While bioequivalent to Accutane® under high fat fed conditions Epuris
provides 83% greater absorption under fasted conditions.1 It is available in 10mg, 20mg, 30mg, and 40mg oral capsules for
flexible, individualized dosing according to the patients weight and
For more information, please visit www.epuris.ca for the full product monograph and for important information about
indications, contraindications, warnings and precautions.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: DND; OTC: CPHMF) is a growing specialty
pharmaceutical company with three commercial products and a fourth in
development. Our product candidates are typically improved formulations
of successful, currently marketed drugs. We in-license a product,
manage the required clinical development and regulatory approval
process, and either out-license it to a marketing partner, or, in
Canada, we may market the product ourselves. Our core capabilities are
in clinical and regulatory affairs, product licensing, supply chain
management, and marketing and sales. Since the Company was founded in
2000, we have achieved final regulatory approval in the U.S. and Canada
for all three of our original products and completed six marketing
partnerships, generating growing licensing revenue.
1. Cipher Pharmaceuticals Inc. Epuris™ Product Monograph. March 14,